Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of anti-cs1 antibodies for treatment of rare lymphomas

A-CS1, lymphoma technology, applied in the field of use of anti-CS1 antibodies for the treatment of rare lymphomas, and can solve problems such as no treatment yet

Inactive Publication Date: 2011-10-12
ABBOTT BIOTHERAPEUTICS CORP +1
View PDF50 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there are no satisfactory treatments for these advanced forms of lymphoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of anti-cs1 antibodies for treatment of rare lymphomas
  • Use of anti-cs1 antibodies for treatment of rare lymphomas
  • Use of anti-cs1 antibodies for treatment of rare lymphomas

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0114] 6. Example 1: CS1 in the nasal type of NK / T cell lymphoma and angioimmunoblasts T-cell lymphoma

[0115] Background: CS1 (CRACC, SLAMF7, CD319) is a member of the signal transduction lymphocyte activation molecule related receptor family. It is highly and uniformly expressed on the cell surface of benign and malignant plasma cells. It has been reported that the level of CS1 is low on NK cells and NK-like T cells (NK / T). Prior to this, CS1 was unknown in NK and T-cell lymphomas—aggressive lymphomas for which no effective treatment exists. The expression of CS1 in normal NK / T cells and a series of NK and peripheral T cell lymphomas (PTCL) was determined.

[0116] Methods: Using automated immunohistochemistry (IHC, Ventana Medical Systems), the expression of CS1 in normal NK and T cells was detected by gene expression profile. Flow cytometry (FACSCalibur, Becton Dickinson) was performed in blood from normal samples using directly conjugated Alexa-488elotuzumab (HuLuc63). ...

Embodiment 2

[0119] Example 2: CS1 in nasal type of NK / T cell lymphoma and angioimmunoblastic Expressed in T cell lymphoma

[0120] 7.1 Introduction

[0121] CS1 (CD319, CRACC, SLAMF7) is a member of the receptor family of signaling lymphocyte activation molecules. It has recently been identified as a cell surface antibody target and is selectively expressed on the surface of plasma cells (Hsi et al., 2008, Clin. Cancer Res. 14: 2775-2784). Other members of the signaling lymphocyte activation molecule (SLAM)-related receptor family include SLAM (CD150), 2B4 (CD244), CD84, NTB-A (Ly-108) and Ly-9 (CD229). These molecules are characterized by 2 or 4 extracellular immunoglobulin (Ig)-like domains and an intracellular signaling domain with an immunoreceptor-based tyrosine conversion motif (which has a consensus amino acid sequence TxYxxV / I) .

[0122] Humanized antibodies against CS1 (elotuzumab, also known as HuLuc63) are currently being studied in relapsed multiple myeloma (Tai et al., 2008, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Uses of anti-CS1 antibodies, alone or in combination with other agents, for the treatment of rare lymphomas, such as NK lymphomas, NK / T-cell lymphomas, and angioimmunoblastic lymphomas.

Description

[0001] Cross references to related applications [0002] This application claims the priority of U.S. Provisional Application No. 61 / 110,295 filed on October 31, 2008 and U.S. Provisional Application No. 61 / 118,244 filed on November 26, 2008 in accordance with 35U.SC§119(e), and their respective contents The full text is incorporated herein by reference. 1. Technical Field [0003] This application relates to the use of anti-CS1 antibodies for the treatment of NK lymphoma, NK / T cell lymphoma and angioimmunoblastic lymphoma. 2. Background technology [0004] CS1 (CD2-subset 1), also known as SLAMF7, CRACC, 19A, APEX-I and FOAP12 (Genbank accession number NM 021181.3), is a member of the CD2 family of cell surface glycoproteins. In normal tissues and CD34 + CS1 is not expressed in stem cells, but it has been reported to express CS1 in primary myeloma, natural killer cells, cytotoxic T cells and activated B cells. [0005] Non-Hodgkin's lymphoma is a cancer of the lymphatic tissues (ly...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/395A61P35/00
CPCA61K2039/505A61P35/00C07K16/2803A61K39/395
Inventor D·阿法尔E·赫斯
Owner ABBOTT BIOTHERAPEUTICS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com